Trial reportVaccine2009
A novel HIV T helper epitope-based vaccine elicits cytokine-secreting HIV-specific CD4+ T cells in a Phase I clinical trial in HIV-uninfected adults.
Trial report in Vaccine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 41 citations in OpenAlex.
- DNA and modified vaccinia virus Ankara vaccines encoding multiple cytotoxic and helper T-lymphocyte epitopes of human immunodeficiency virus type 1 (HIV-1) are safe but weakly immunogenic in HIV-1-uninfected, vaccinia virus-naive adults.Clinical and vaccine immunology : CVI · 2012Trial
- Article
- Reverse Vaccinology Approach in Constructing a Multi-Epitope Vaccine Against Cancer-Testis Antigens Expressed in Non-Small Cell Lung Cancer.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- Immunoinformatics prediction of overlapping CD8Vaccine · 2021Article
- Identification and selection of immunodominant B and T cell epitopes for dengue multi-epitope-based vaccine.Medical microbiology and immunology · 2021Review
- In Silico Approach in Designing a Novel Multi-Epitope Vaccine Candidate against Non-Small Cell Lung Cancer with Overexpressed G Protein-Coupled Receptor 56.Asian Pacific journal of cancer prevention : APJCP · 2020Article
- Overlapping CD8+ and CD4+ T-cell epitopes identification for the progression of epitope-based peptide vaccine from nucleocapsid and glycoprotein of emerging Rift Valley fever virus using immunoinformatics approach.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2017Article
- A recombinant multi-epitope protein MEP1 elicits efficient long-term immune responses against HIV-1 infection.Human vaccines & immunotherapeutics · 2017Article
- A novel polyepitope vaccine elicited HIV peptide specific CD4+ T cell responses in HLA-A2/DRB1 transgenic mice.PloS one · 2017Article
- Article
- Recombinant and epitope-based vaccines on the road to the market and implications for vaccine design and production.Human vaccines & immunotherapeutics · 2016Article
- Article
- Multiple factors affect immunogenicity of DNA plasmid HIV vaccines in human clinical trials.Vaccine · 2015Article
- In silico design of a DNA-based HIV-1 multi-epitope vaccine for Chinese populations.Human vaccines & immunotherapeutics · 2015Article
- Advances in the study of HLA-restricted epitope vaccines.Human vaccines & immunotherapeutics · 2013Review
- Novel directions in HIV-1 vaccines revealed from clinical trials.Current opinion in HIV and AIDS · 2013Review
- Protective immunity against Trichinella spiralis infection induced by a multi-epitope vaccine in a murine model.PloS one · 2013Article
- Resistance-associated epitopes of HIV-1C-highly probable candidates for a multi-epitope vaccine.Immunogenetics · 2012Article
- Non-condensing polymeric nanoparticles for targeted gene and siRNA delivery.International journal of pharmaceutics · 2012Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 1 country.
Funding
Abstract
A Phase I human vaccine trial of a novel polypeptide vaccine of HIV T helper epitopes (EP-1043) and a DNA vaccine of HIV CTL epitopes was conducted in 84 healthy adult volunteers. The vaccine immunogenicity was assessed by an intracellular cytokine staining assay for IL-2, IL-4, TNF-alpha and IFN-gamma. Sixty eight percent (32/47) of subjects had a positive CD4+ T response after receiving two vaccinations of the polypeptide vaccine. The responding CD4+ T cells made various combinations of IL-2, IL-4, IFN-gamma, and TNF-alpha. The study demonstrated that the EP-1043 vaccine is safe, well-tolerated, and immunogenic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.